Journal
TRANSPLANTATION PROCEEDINGS
Volume 53, Issue 7, Pages 2346-2353Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.transproceed.2021.07.049
Keywords
-
Categories
Ask authors/readers for more resources
Liver transplantation is currently the most effective treatment for chronic and acute liver diseases, but patients may develop bone metabolic disease as a chronic complication, increasing the risk of fractures. During the first year post-transplantation, patients experience greater bone loss and should be diagnosed for osteoporosis using bone mineral density and other risk factors.
Liver transplantation is currently the most effective and almost routine treatment for chronic and acute liver diseases. The survival of transplanted patients has increased exponentially, which has led to more knowledge of the long-term complications secondary to the underlying pathology or the various treatments that must be followed. Bone metabolic disease is a chronic complication of liver transplantation that inhibits quality of life. The factors that contribute to the development of bone disease are different according to the various etiologies of liver damage. All patients should be examined for osteoporosis risk factors because the incidence of new fractures in transplant patients is higher during the first year after transplantation, reflecting the greater bone loss during this time. This article outlines a proposal for a treatment algorithm; we propose that pharmacologic therapy in patients post liver transplant should first consider the diagnosis of osteoporosis by bone mineral density, the patient's personal and family history of spine and femoral neck fractures, and the use glucocorticoids (dose and time) until a tool is available that allows the best estimation of the fracture risk in this population of patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available